Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis | Zendy

Alberto Ortíz | Zendy; Steve Kanters | Zendy; Alaa Hamed | Zendy; Pronabesh DasMahapatra | Zendy; Eugene Poggio | Zendy; Manish Maski | Zendy; Mario Aguiar | Zendy; Elvira Ponce | Zendy; Jeroen P. Jansen | Zendy; Dieter Ayers | Zendy; Rachel Goldgrub | Zendy; Robert J. Desnick | Zendy

Open Access

Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis

Author(s) -

Alberto Ortíz,

Steve Kanters,

Alaa Hamed,

Pronabesh DasMahapatra,

Eugene Poggio,

Manish Maski,

Mario Aguiar,

Elvira Ponce,

Jeroen P. Jansen,

Dieter Ayers,

Rachel Goldgrub,

Robert J. Desnick

Publication year - 2020

Publication title -

clinical kidney journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.033

H-Index - 40

eISSN - 2048-8513

pISSN - 2048-8505

DOI - 10.1093/ckj/sfaa065

Subject(s) - medicine , renal function , fabry disease , confidence interval , urology , kidney disease , proteinuria , disease , kidney

Fabry disease is a rare, X-linked genetic disorder that, if untreated in patients with the Classic phenotype, often progresses to end-stage kidney disease. This meta-analysis determined the effect of agalsidase beta on loss of estimated glomerular filtration rate (eGFR) in the Classic phenotype using an expansive evidence base of individual patient-level data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research